(Q24240879)

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Induction interferon and ribavirin for re‐treatment of chronic hepatitis C patients unresponsive to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin therapy in chronic delta hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A pilot study of ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Pilot study of ribavirin and interferon-beta for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Hepatitis C recurrence in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin: a possible alternative for the treatment of chronic non-A, non-B hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin treatment for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Treatment with Ribavirin+Alpha Interferon in HCV Chronic Active Hepatitis Non-Responders to Interferon Alone: Preliminary Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Teratogenic effects of ribavirin on hamster and rat embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Hepatitis C virus infection: quality of life and side effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Hepatitis C: the clinical spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Recent advances: hepatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Ribavirin: current role in the optimal clinical management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

The impact of diagnosis of hepatitis C virus on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Cost effectiveness of combination therapy for hepatitis C: a decision analytic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

7 January 2021

Changes in hepatitis C virus antigen in liver with antiviral therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

7 January 2021

Decisions, decisions, decisions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

7 January 2021

American Gastroenterological Association medical position statement on the management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

7 January 2021

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445.PUB2

7 January 2021

10.1002/14651858.CD005445.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20091577

1 reference

Consolidated OpenCitations Corpus – April 2017